Provention Bio, Inc.: insider trades · United States · SEC (Form 4)

About Provention Bio, Inc.

Provention Bio, Inc. was a U.S.-based clinical-stage biopharmaceutical company focused on intercepting and preventing immune-mediated diseases, with a particularly strong emphasis on type 1 diabetes. The company was incorporated in Delaware in 2016 and maintained its principal operational base in Red Bank, New Jersey, United States. For French-, Belgian-, and Swiss-based investors, Provention Bio represented a classic high-risk, high-catalyst biotechnology profile: valuation depended primarily on clinical development progress, regulatory milestones, and strategic transaction outcomes rather than on mature commercial scale. Before being acquired, the company was listed on the NASDAQ market in the United States, placing it squarely in the segment of growth-oriented biotech names where investor sentiment is highly sensitive to trial data and FDA decisions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1695357/000149315222030280/R7.htm?utm_source=openai)) Its flagship asset was TZIELD (teplizumab-mzwv), a first-in-class anti-CD3 therapy designed to delay the onset of type 1 diabetes in selected high-risk patients. That asset gave Provention Bio a clearly differentiated market position: instead of competing in crowded symptomatic treatment markets, the company targeted early intervention in autoimmune disease progression. This focus on disease interception was central to the company’s identity and helped distinguish it from broader immunology or diabetes developers. Provention also pursued additional programs in immune-mediated and autoimmune indications, reinforcing its positioning as a science-led biotech platform built around prevention rather than conventional chronic-disease management. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1695357/000149315222030280/R7.htm?utm_source=openai)) From a competitive standpoint, Provention Bio’s strength lay in its narrow but potentially category-defining therapeutic thesis. The company’s differentiation stemmed from having a first-in-class asset with meaningful clinical and strategic appeal, rather than from breadth of revenue streams or geographic reach. That also meant concentration risk was high: a small number of programs had outsized influence on enterprise value, which is typical for NASDAQ-listed biotech companies at this stage. Its geographic footprint was primarily U.S.-based, with no indication of a broad global commercial infrastructure prior to acquisition. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1695357/000149315222030280/R7.htm?utm_source=openai)) The most important recent corporate event was Sanofi’s acquisition of Provention Bio. On March 13, 2023, Sanofi announced an all-cash agreement to buy Provention Bio for $25.00 per share, implying an equity value of approximately $2.8 billion. The transaction was completed on April 27, 2023, and Provention Bio common stock ceased trading on NASDAQ that same day. As a result, Provention Bio is no longer an independently listed company; today it is best understood as a strategic acquisition that brought TZIELD into Sanofi’s portfolio. For investors reviewing historical SEC Form 4 insider activity, that means Provention Bio should be treated as a legacy listed issuer rather than an active public equity. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1695357/000149315223007347/ex99-1.htm?utm_source=openai))